* A corporate client of Hybridan LLP
** Arranged by type of listing and date of announcement
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced
Dish of the day
Admissions:
None
Delistings:
None
What’s baking in the oven? **
Potential**** Initial Public Offerings:
None
Reverse Takeovers:
None
Change of Market:
None
Banquet Buffet***
Aquis Exchange 352p £96.9m (AQX.L)
Aquis Exchange announces that it has been awarded the contract to provide the Central Bank of Colombia, Banco de la República, with the technology and support services for the operation of its government bond market. The Group's software and technology division will be deploying its state-of-the-art trading platform and services to facilitate the modernisation of the Colombian government bond market, with enhancements to efficiency, transparency and accessibility.
undefinedCora Gold 1.95p £7.2m (CORA.L)
The West African focused gold Company provided an update on its capital structure. Following the conversion on 27 February 2024 of an aggregate amount of US$2,278,500 of convertible loan notes in the capital of the Company, out of a total issued and outstanding CLN of US$12,971,500 matured on 12 March 2024. After repayment of the outstanding CLN at a 5% premium to the total amount outstanding under the CLN, the Company's balance of cash and cash equivalents is in excess of US$2.9m.
EARNZ 0.1p £1m (EARN.L)
The development and commercialisation of clean technologies Company announces the appointment of Elizabeth Lake as a Non-Executive Director with immediate effect. Elizabeth is an accomplished executive with more than 25 years of finance and commercial experience. Previously, Elizabeth joined the board of Revolution Beauty Group as CFO in May 2022 and was instrumental in turning around the business following the suspension of its shares from trading on AIM.
IXICO 7.125p £3.4m (IXI.L)
The medical imaging advanced analytics Company delivering insights in neuroscience announces a trading update for the year ending 30 September 2024. Delays to the anticipated project start dates for these new contracts are likely to result in FY 2024 revenues of £5.2m - £5.9m, with an equivalent anticipated impact on FY 2025. The Company has a strong balance sheet with £2.8m of cash at 29 February 2024 and no debt.
MaxCyte 31.7p £328.9m (MXCT.L)
The cell-engineering focused Company providing enabling platform technologies to advance the discovery, development, and commercialisation of next-generation cell therapeutics and innovative bioprocessing applications announces its fourth quarter and full year ended December 31, 2023. Revenue is down 7% to $41m (FY: 22: 44m), EBITDA is a loss of $44.1m (FY 22: $24.8m) and the total cash is down to $211.2m (FY 22: $227.3). Management expects full year 2024 core business revenue to be flat to 5% growth compared to 2023, and SPL Program-related revenue is expected to be approximately $3m.
MusicMagpie 8.75p £9.4m (MMAG.L)
The circular economy pioneer specialising in refurbished consumer technology, disc media and books in both the UK and US announces its audited full year results for the year ended 30 November 2023. Revenue decreased 6% to £136.6m (FY 22: £145.3m), adjusted EBITDA increased 15% to £7.5m (FY 22: 6.5m), and the loss before tax increased to £6.8m (FY 22: 1.5m). Furthermore, Net Debt increased to £13.1m (FY 22: £7.9m). Q1 FY24 has recently closed and trading was in line with management's expectations.
Nexteq 150p £99.8m (NXQ.L)
The technology solutions provider to customers in selected industrial markets announces its audited full year results for the 12 months ended 31 December 2023. Revenue decreased 5% to $114.3m (FY 22: $119.9m) and the Group Profit before tax increased 47% to $12.9m (FY 22: $8.8m). Furthermore, the net cash increased 116% to $27.9m (FY 22: $12.9m). A strong balance sheet with net cash position and good operational liquidity; supported by good cash generation, positions the Group for future organic and acquisitive growth.
Sareum Holdings* 22.5p £15.8m (SAR.L)
The clinical-stage biotech Company developing next-generation kinase inhibitors for autoimmune disease and cancer yesterday indicated that it expects to report an operating loss of £2.5m (2022: loss of £1.7m) for the half-year to 31 December 2023, reflective of the cost for the clinical research of its SDC-1801 programme. Sareum will report its results during the week of the 25th March. Meanwhile, Sareum has drawn £2.3m to date under its Equity Prepayment Facility with RiverFort Global Opportunities PCC Ltd. Sareum currently has an outstanding balance of circa £1.3m under the Facility, which it owes to Riverfort, and it expects to settle it by the issuance of shares prior to the Maturity Date in August 2025. In accordance with the terms of the Facility, Sareum has now issued a further 1.5m shares. Providing alternative funding is secured, the Board remains confident that the Company is on course to deliver SDC-1801 topline Phase 1a results in Q2 2024.
Seraphim Space Investment Trust 57p £135.2m (SSIT.L)
The SpaceTech Investment Company announces its interim results for the six month period ended 31 December 2023. The NAV increased 0.9% to £224.3m (H1 FY 23: £222.4m), the portfolio valuation increased 5.6% to £198m (H1 FY 23: £187.4m). 82% of the portfolio by fair value has a robust cash runway, with 60% fully funded based on latest projections from the companies' management teams and 22% funded for 12 months or more from 31 December 2023. We are cautiously optimistic about improving macroeconomic conditions and continued positive momentum within the SpaceTech investment market.
The Gym Group 117p £209.1m (GYM.L)
The low cost gym operator announces its full year results for the year ended 31 December 2023. Revenue increased 18% to £204m (FY 22: 172.9m) and Group Adjusted EBITDA increased 6% to £75.5m (FY 22: £71.3m). Free cash Flow increased 62% to £27m (FY 22: £16.7m). The Company reported a good start to trading in 2024; revenue after two months has grown by 16% year on year, reflecting a 3% increase in average members and 13% growth in yield, benefitting from price taken earlier in the year. Like-for-like revenue up 12%.
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.